Predicting Lupus Flares with Mycophenolate Mofetil Levels
Author Information
Author(s): Djabarouti Sarah, Breilh Dominique, Duffau Pierre, Lazaro Estibaliz, Greib Carine, Caubet Olivier, Saux Marie-Claude, Pellegrin Jean-Luc, Viallard Jean-François
Primary Institution: Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux
Hypothesis
Can mycophenolate mofetil pharmacokinetics predict clinical flares in systemic lupus erythematosus patients?
Conclusion
Lower mycophenolate mofetil levels are associated with increased risk of clinical flares in lupus patients.
Supporting Evidence
- Patients with lower mycophenolate levels had a higher rate of disease flares.
- A threshold of 3 mg/L for mycophenolate levels predicted flares with 92% negative predictive value.
- The study followed patients for six months to assess clinical outcomes.
Takeaway
Doctors can tell if lupus patients might have a flare by checking their medicine levels. If the levels are too low, it could mean trouble.
Methodology
The study measured drug levels in blood samples from lupus patients and tracked their disease activity over six months.
Potential Biases
Potential bias due to the observational nature of the study and the exclusion of patients with renal involvement.
Limitations
The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
26 Caucasian patients with systemic lupus erythematosus, without renal manifestations.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI 0.71 to 1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website